Company: ABBV
Filing Date: 2025-03-10
Form Type: PRE 14A
Source: 0001558370-25-002603
Chunk: 34

Company: AbbVie Inc.
Filing Date: 2025-03-10
Form: PRE 14A
Chunk 34
---
 foreign exchange and other specified adjustments and/or unusual or unpredictable events, and the appropriateness of these adjustments is reviewed annually by the committee. In 2024, specified adjustments included intangible asset amortization, acquisition and integration-related costs, IPR&D and milestones expense, change in fair value of contingent consideration, impacts related to the settlement of income tax examinations and changes in income tax reserves, and other items, as described in Appendix B. In 2024, our NEOs continued to take a formal goal aligned to driving AbbVie’s environmental, social, and governance (ESG) framework. The ESG goal was weighted 10% within the short-term incentive program for each NEO. As part of this ESG goal category, all senior leaders, including the NEOs, continued to take a goal aligned to executing the equity, equality, diversity, and inclusion (EEDI) strategy. AbbVie’s senior executives have different areas of focus when it comes to driving the company’s ESG framework, and together, the executives’ ESG accomplishments under this goal cover all of AbbVie’s material ESG drivers. Example achievements under the ESG goal category in 2024 by AbbVie’s senior executives included, for example:

| ● | Over 235,000 U.S. patients were provided medicine at no cost through our patient assistance program in 2024. |

| ● | Decreased our Scope 1 and 2 emissions by more than 26% in 2024 compared to our 2021 baseline, positioning us well to meet our 42% Scope 1 and 2 emissions reduction target by 2030. |

| ● | Over 13,000 AbbVie employees in nearly 60 countries and territories donated more than 47,000 volunteer hours during AbbVie’s annual Week of Possibilities volunteer event. |

Our EEDI strategy includes specific priority areas to ensure AbbVie fosters a culture that is inclusive and innovative – in service of our people, patients, and business. 2024 progress on this strategy includes:

| ● | Fostering an inclusive workplace. Developing and delivering innovative life-changing medicines for our diverse patient population with unique health challenges, requiring thoughtfulness and creativity that comes from a wide range of inputs. With this viewpoint in mind, we continued to design and implement |

2025 Proxy Statement |43

| ​                      | ​ |
| EXECUTIVE COMPENSATION | ​ |

| talent attraction, sourcing, and hiring solutions, as well as